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Summary Thyroid carcinomas are heterogeneous in terms of histology, clinical presentation, treatment
response and prognosis. Since bcl-2 and p53 gene alterations are frequently involved in both lymphoid and
epithelial malignancies, we analysed the expression of bcl-2, p53 and proliferating cell nuclear antigen (PCNA)
in a group of 134 patients with thyroid neoplasms. The same markers were evaluated in fetal and adult normal
thyroids as well as in 40 benign lesions. The study was carried out by immunocytochemistry on archival
material using antibodies against bcl-2 and p53 protein on tissue sections of 40 adenomas (As), 20 medullary
carcinomas (MCs), 70 well-differentiated carcinomas (WDCs), 20 poorly differentiated carcinomas (PDCs) and
24 undifferentiated carcinomas (UCs). bcl-2 immunoreactivity was detected in 36 out of 40 (90%) As, 20 out
of 20 (100%) MCs, 60 out of 70 (85.7%) WDCs, 20 out of 20 (100%) PDCs, and 8 out of 24 (33.3%) of UCs.
p53 expression was present in 11.4% ofWDCs, 5% of PDCs, 5% of MCs and 62.5% of UCs. By contrast, no
p53 immunoreactivity was detected in 40 adenomas and in all the normal thyroid tissues studied. We observed
a positive correlation between the expression of p53 and PCNA (r = 0.42; P = 0.035) in a group of UCs, but
not in WDCs, PDCs and MCs. Neither p53 nor bcl-2 expression were correlated with clinicopathological
parameters, such as age, sex, pTNM and survival. Our results suggest that in tumours of the follicular
epithelium p53 and bcl-2 protein abnormalities are associated with more advanced carcinomas and especially
with undifferentiated carcinomas, while they are only rarely altered in tumours of the parafollicular C cells.
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The protein encoded by the bcl-2 proto-oncogene is im-
plicated in the prolongation of cell survival by blocking
programmed cell death, i.e. apoptosis (Reed, 1994). The bcl-2
gene is located on band q21.3 of the human chromosome 18
and was first described as a result of the chromosomal trans-
location t(14;18) present in a majority offollicular B cell lines
(Tsujimoto et al., 1987). It is also known that 85% of human
follicular B-cell lymphomas showed a translocation of the
bcl-2 gene on the immunoglobulin heavy-chain locus of
chromosome 14, resulting in deregulated bcl-2 expression
(Tsujimoto et al., 1985). In this type of neoplasia the protein
product of the bcl-2 gene provides a growth advantage and
may inhibit apoptosis. Recently, the bcl-2 protein has also
been detected in a limited number of non-lymphoid tissues
under different physiological conditions: (1) long-lived stem
cells from complex differentiating epithelium such as skin and
intestine; (2) long-lived post-mitotic cells such as neurons;
and (3) glandular epithelium in which hormone and growth
factors regulate hyperplasia and involution (Hockenbury et
al., 1991).
Since thyroid cancer is a typical example of tumour
originating from a hormone-dependent tissue that maintains
original hormonal dependency, at least in the group of
differentiated carcinomas, we evaluated bcl-2 protein expres-
sion both in physiological (fetal and normal adult tissue) and
in pathological conditions (benign and malignant tumours) of
the thyroid gland. In addition, bcl-2 protein expression was
correlated with p53 and proliferating cell nuclear antigen
(PCNA) immunoreactivity in well-differentiated carcinomas
(WDCs), poorly differentiated carcinomas (PDCs),
undifferentiated carcinomas (UCs) and medullary carcinomas
(MCs). The possibility of following the clinical history of
most of the patients allowed us to investigate the relationship




The study was carried out on 134 patients who had primary
malignant thyroid tumours. Histotype was WDC in 70
patients (47 papillary and 23 follicular), PDC in 20, MC in
20 and UC in 24 patients. We also studied 40 benign
tumours (micro- and macrofollicular adenomas) and ten fetal
tissues. This series of thyroid tumours is part of a larger
series of thyroid cancer patients followed at the Institute of
Endocrinology, which is a referral centre for thyroid car-
cinomas in Italy. We studied all patients who received
primary surgical treatment at the University of Pisa and
whose tissues were available at the Department ofPathology.
For this reason the series is to some degree selected and the
histotype distribution does not reflect the biological history
of thyroid carcinomas.
Initial treatment was total (near-total) thyroidectomy in all
patients regardless of the histotype. Lymph node dissection
was performed in MCs, but not in WDCs, for which lymph
node dissection was performed only in the case of evident
node involvement. Post-surgical treatment included 13'1
therapy for WDCs and PDCs (if iodine uptake of whole-
body scan (WBS) with "'lI was demonstrated) followed by
1-thyroxine suppressive therapy. MCs and PDCs (with no
iodine uptake) were treated with chemotherapy and/or
radiotherapy in case of recurrence or distant metastases. UCs
were treated with total thyroidectomy whenever possible,
followed by external radiotherapy and/or chemotherapy. All
patients were regularly followed up by physical examination,
chest roentgenogram and WBS with '3'I (differentiated
thyroid cancer).
Immunohistochemistry
Immediately after surgery, the tissues were fixed in 10%
formalin, embedded in paraffin and stained with haematox-
ylin and eosin.
bcl-2 expression Paraffin sections (3-5 i.m) were dewaxed in
xylene and rehydrated through graded alcohols. Sections
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were blocked with 10% normal rabbit serum for 30 min
before the addition of monoclonal antibody against bcl-2
(MAb 124, DBA Italia, Milan, Italy) for 18-24 h at 1:20 of
dilution. The alkaline phosphatase-anti-alkaline phosphatase
(APAAP) method (Cordell et al., 1984) was then used to
amplify the primary antibody signal; the sections were
incubated with rabbit anti-mouse antibody for 30min, and
then with mouse monoclonal APAAP for another 30min.
These two steps were then repeated once for 10min each.
The reaction was revealed with alkaline-phosphatase subs-
trate containing naphthol AS-MX, fast-red and levamisol
(APAAP kits, Dako, Milan, Italy), yielding an insoluble red
reaction product. Sections were counterstained with Gill's
haematoxylin and then mounted in aqueous mounting
medium. Formalin-fixed paraffin-embedded sections from
tonsillar tissue were used as positive control. As negative
control we used phosphate-buffered saline (PBS) instead of
primary MAb.
p53 and PCNA expression Sections of 3-5 fLm were stained
using the avidin-biotin-peroxidase complex (ABC) method
(Hsu et al., 1981). Deparaffinised sections were treated with
0.3% hydrogen peroxidase in methanol for 30min to block
the endogenous peroxidase. In order to unmask the p53
epitopes we microwaved the sections in 10 mm citrate buffer,
pH 6.0 (Cattoretti et al., 1992). After 20 min incubation with
goat normal serum, polyclonal p53 antiserum (NCL-CM1,
Novocastra Laboratories) diluted 1:1000, was applied for
18-24 h. The sections were then incubated with 1:200 dilu-
tion of biotin-labelled secondary antibody for 30 min and
ABC (Vector, Burlingame, CA, USA) for 45 min. Subse-
quently, sections were stained for 5 min with 0.05% 3,3-
diaminobenzidine tetrahydrochloride, 0.01% hydrogen perox-
ide-in 0.05 M Tris-HCl buffer pH 7.6, counterstained with
haematoxylin, dehydrated and mounted. Paraffin-embedded
sections of a lung carcinoma with a confirmed mutation of
p53, and which were unequivocally immunoreactive for p53,
were included in each series as positive controls. Negative
controls consisted in the replacement of the polyclonal
primary antiserum with normal rabbit serum at the same
dilution as the primary antiserum. PCNA immunostaining
was performed on formalin-fixed paraffin sections of the
same cases, using PCIO monoclonal antibody (dilution 1:200)
as primary antibody. The sections were microwaved. The
PCNA immunoreactivity was revealed using an ABC
method. For negative control we used phosphate-buffered
saline (PBS) instead of the primary MAb.
Immunohistochemical evaluation Each section was carefully
examined for the presence of nuclear immunostaining for p53
and PCNA and cytoplasmic immunoreactivity for bcl-2. The
areas displaying more numerous stained nuclei were selected
for counting. At least 1000 cells were counted for each case.
The tumours were considered as p53 or bcl-2 positive when
at least 5% of positive cells were reactive.
Statistical analysis
The STATISTICA (Stat-Soft) package was used for statis-
tical analysis and the following tests were employed: (1)
Kruskal-Wallis ANOVA median test; (2) Fisher's exact test;
(3) Spearman correlation.
Results
The clinicopathological profile of 134 cancer patients is
reported in Table I. As expected the mean age of UC
patients was older than that of patients with differentiated
tumours, and females were more affected than males. Deaths
were more frequent in UC (95.8%) than in all other his-
totypes.
bcl-2 protein expression
Immunostaining for bcl-2 was evaluated in 134 thyroid car-
cinomas, 40 adenomas and on ten fetal thyroids and 100
unaffected thyroid tissues adjacent to tumour used as control.
Table I Clinicopathological parameters in 134 thyroid carcinomas
Variables WDC PDC UC MC
No. of cases 70 20 24 20
Age (mean ± s.d.) 49.2 ± 17 42.2 ± 22 65.7 ± 11.6 53.9 ± 17
Sex
M 22 6 8 7
F 48 14 16 13
T
1 8 3 0 1
2-3-4 40 13 21 14
X 16 4 3 5
N
0 27 9 15 7
1 26 9 7 9
X 17 2 2 4
Follow-up
Alive 63 15 1 16
Dead 7 5 23 4
Table II bcl-2 and p53 protein expression in normal and neoplastic thyroid tissues
p53-positive cases" bcl-2-positive casesb
Histological type No. ofcases No. % No. %
Fetal thyroid 10 Not done 10 100
Normal tissue adjacent to tumour 100 0 0 100 100
Adenoma 40 0 0 36 90
WDC 70 8 11.4c 60 85.7
PDC 20 1 5d 20 100
Uc 24 15 62.5d 8 33.3
MC 20 1 5c 20 100
a Weconsidered aspositive cases those tumourswith more than 5% ofp53-immunoreactive nuclei.
We considered as positive cases those tumours with more than 5% of bcl-2-immunoreactive cell
cytoplasm. Pattern of immunopositivity: c focal; d diffuse and strong.
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iAs reported in Table II, 100% of both fetal and normal adult
thyroids express bcl-2 protein. Thirty-six out of 40 (90%)
adenomas, 60 out of 70 (85.7%) WDCs, 20 out of 20 PDCs
(100%), and 20 out of 20 (100%) MCs strongly
immunoreacted with MAb against the bcl-2 protein. By con-
trast, the bcl-2 protein in UCs was expressed in only 8 cases
out of 24 (33.3%). (Figure la and b).
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P53 protein exvrwessiion
Immunostaining for p53 was evaluated in both neoplastic
lesions (40 adenomas and 134 carcinomas) and in normal
adult thyroid tissue. Normal tissues and adenomas fail to
overexpress the p53 protein while eight WDCs, one PDC and
one case of MC showed p53 immunopositivity (Table II). By
contrast, 62.5% of UCs revealed p53 expression in most of
the neoplastic cells (Figure Ic). Furthermore, in WDCs and
MCs the positive nuclei were always limited to scattered foci
of cells, while in UCs and PDCs positive cases showed a
strong and diffuse pattern of staining.
PCNA evpre.ssion
As shown in Figure 2, the percentage of positive cells fails to
show significant differences between WDCs, PDCs and MCs.
By contrast, UCs showed a significantly higher PCNA ex-
pression compared with the other histotypes (non-parametric
Kruskal-Wallis test; /' = 15.44; P = 0.0015).
Correlaitioni bemteen heb1-2, PCNA andp53 proteini expresvsion
When the data were analysed pooling all the histotypes, bcl-2
protein expression showed a strong inverse relationship with
p53 protein expression (Spearman test; r = -0.281,
P = 0.0009), while no correlation was found between bcl-2
and PCNA (Spearman test; r -0.1 38, P = 0.11). In addi-
tion, the percentage of p53-immunoreactive cells was directly
correlated with the proliferative activity evaluated as PCNA
expression (Spearman test; r = 0.314, P = 0.00021). However,
when the results were analysed separately for each histotype
no correlation was found between the three parameters with
the exception of the group with UCs, in which a positive
correlation was found between p53 and PCNA expression
(Spearman test; r = 0.43; P = 0.035).
No correlation was found between p53 or bcl-2 expression
and age, sex, TNM status and survival (data not shown).
Discussion
In the present study we demonstrated by immunohis-
tochemistry bcl-2 expression in most of the differentiated
tumours arising both from follicular and parafollicular C
cells of the thyroid, and only in a minority of the
undifferentiated tumours. The opposite finding was found
with p53 protein expression, which rarely overexpressed in
differentiated tumours. PCNA, a marker of cell proliferation,
was significantly increased in UCs compared with the other
subgroups of carcinoma. Furthermore, we found that bcl-2
expression was inversely correlated with p53 protein, while








Figure 1 Well-differentiated carcinoma: papillary (a) thyroid
caincers (follicular variant) showing bcl-2-positive immunostained
cclls. (b) Arca of undifferentiated thyroid cancer (arrows)
ncgative for bch-2 immunorcactivity. (c) Scveral nuclci of neoplas-
tic cells imnmunopositive for p53 proteini (arrows).
0
A WDC PDC MC UC
Figure 2 PCNA expression in adenoma and well-differentiated,
poorly differentiated, undifferentiated and medullary thyroid car-
cinomas. P= 0.0015.p53x bd-2cproer.-in &Fcauw
L Pobna et t
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The bcl-2 proto-oncogene was shown to confer resistance
to apoptotic cell death (Raff et al., 1993) and is topog-
raphically restricted to the long-lived progenitor cells that
renew these lineages and select post-mitotic cells requiring an
extended life-span (Hockenbery et al., 1990). Hockenbury et
al. reported bcl-2 protein expression not only in all the
haematopoietic lineages but also in some normal non-
lymphoid tissues including breast, prostate, pancreas, intes-
tine, skin, nervous system and thyroid gland. In particular,
the same authors found that all the cells in the follicular
epithelium appeared to be stained.
We obtained the same results in the normal thyroid tissue
adjacent to the tumours and in ten fetal thyroids studied. It
has also been recently reported (Pilotti et al., 1994) that the
majority of WDCs and PDCs co-expressed bcl-2 protein and
Tg, whereas almost all cases of UC were negative for both.
As suggested by the authors, these results indicate an inverse
correlation between bcl-2 expression and both loss of
differentiation and neoplastic progression. Our data agree
with Pilotti's results where almost all undifferentiated cancers
express bcl-2 protein, which is however expressed by only a
small percentage of undifferentiated tumours. Interestingly,
we have found that 100% of MCs express bcl-2 protein. The
reason for this finding is not clear at present. However, since
bcl-2 is also present in several endocrine cells (Hockenbury et
al., 1991), it is not surprising that MCs produce bcl-2 pro-
tein. On the contrary, the bcl-2-positive phenotype is par-
tially abrogated in the more advanced stages of thyroid
tumorigenesis. As a matter of fact, only 8 out of 24 UC cases
were bcl-2 positive, although the percentage of immunoreac-
tive tumours was higher than that reported by Pilotti et al.
(1994).
It has been suggested that p53 and bcl-2 have opposite
functions: p53 is a death pathway gene (Yonisch-Rouach et
al., 1991) and bcl-2 is an antidote to programmed cell death
(Hockenbery et al., 1990). Aberrations in both functions
could lead to extended survival of neoplastic cells and the
increased likelihood of mutational aberrations in other
oncogenes. such as those responsible for growth and pro-
liferation or tumour-suppressor genes.
We have reported (Pacini et al., 1994) p53 overexpression
in the majority of UCs. Results from our group and others
(Dobashi et al., 1993; Levine et al., 1994; Pilotti et al., 1994;
Soares et al., 1994) fit with the high frequency of p53 muta-
tion(s) demonstrated by Fagin et al. (1993) and Ito et al.
(1992) in the same type of thyroid tumours, suggesting a
good correlation between accumulation of p53 protein to
levels detectable by immunohistochemistry and the presence
of p53 point mutation(s) (Wynford-Thomas, 1992). On the
contrary, it has been reported that p53 alterations, studied
both with immunocytochemistry and molecular biology
analysis, rarely occur in WDCs as well as in MCs (Ito et al.,
1993; Holm and Nesland, 1994; Levine et al., 1994). Our
results are in agreement with the above-mentioned authors
and suggest that p53 alteration might be involved in the
progression from PDC to UC.
Since it has been demonstrated that in the wild type, but
not in the mutant form, p53 can inhibit cell proliferation by
blocking entry into the S-phase of the cell cycle (Mercer et
al., 1984; Volgelstein and Kinzler, 1992), we analysed the
correlation between tumour-cell kinetics measured by the
PCNA index and the p53 gene alterations. Already reported
in other human cancers such as breast, colorectal and
oropharyngeal (Pignatelli et al., 1992; Merlo et al., 1993;
Bourhis et al., 1994) a good correlation was observed
between the two markers. This supports the hypothesis that
p53 loss contributes to the deregulation of cell-cycle control
in vivo (Lane and Benchimol, 1990).
Evidence that p53 alterations in thyroid cancers are possi-
ble prognostic factors is unconvincing. Although Dobashi et
al. (1993) have reported that p53 overexpression in this type
of tumour may act as a prognostic indicator, we failed to
show any difference in the presence of proteins between dead
and living patients within the same histotype. We believe that
the high frequency of p53 abnormalities observed in UC
indicates a crucial role of this oncosuppressor gene in the
undifferentiated form of thyroid carcinomas.
From a clinical point of view, in cancers arising from the
follicular thyroid epithelium, the factors considered as impor-
tant prognostic indicators are age, tumour grade, tumour
extension and tumour size (Hay, 1990). The evaluation of
oncogene-encoded proteins has been used to define new prog-
nostic indicators in several human malignancies, including
thyroid tumours (Basolo et al., 1994). In the present study we
failed to show any correlation between oncogene-encoded
proteins and other prognostic factors as well as the patient's
survival. Only those patients who died of undifferentiated
tumours were strictly associated with p53 expression, but this
correlation was not a significnt independent variable due to
the very poor prognosis of this histotype. However, the
finding of the presence of the bcl-2 expression and lack of
p53 expression in the same tumour may be reported as an
index of good differentiation of the tumour.
In conclusion, our study indicates that the exploration of
gene-encoded proteins may give new insights into the unders-
tanding of the mechanism of thyroid tumorigenesis and of
the relevant proto-oncogenes controlling the thyroid cell
cycle.
Abbrve
A, adenoma; WDC, well-differentiated carcinoma; PDC, poorly
differentiated carcinoma; MC, medullary carcinoma; UC,
undifferentiated carcinoma; WT, wild type; MT, mutant type.
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